Hardware Plasmapheresis Use for Correction of Aging Biomarkers in Healthy Patients Aged 40–60 Years: an Original Study

Abstract

INTRODUCTION. Due to the demographic aging of the population, the problem of treatment of age-related diseases and prevention of premature aging in modern healthcare has become particularly urgent. One of the most promising approaches is the impact on the molecular mechanisms of aging, including the activation of adaptive systems and suppression of pathological processes in the body. Methods of extracorporeal hemocorrection have proved to be a good idea in this respect. AIM. To evaluate the effectiveness and safety of hardware plasmapheresis as a technology for correcting aging biomarkers. MATERIAL AND METHODS. A technique of therapeutic plasmapheresis use was introduced for the correction of aging biomarkers. Twenty-four participants (male and female) aged 4060 years with an elevated level of one or more aging biomarkers underwent a course of therapeutic plasmapheresis in the daytime hospital. All participants underwent four procedures of therapeutic hardware plasmapheresis once every 3 days with 30 % volume of circulating plasma followed by replacement with colloid (5 % albumin solution) and crystalloid solutions (saline solution) in a 1:3 ratio or only crystalloid solutions. RESULTS AND DISCUSSION. A comparative evaluation of aging biomarkers before the procedure and 17 and 30 days after hardware plasmapheresis showed that therapeutic plasmapheresis affects the levels of human aging biomarkers in blood. A significant decrease in the levels of such biomarkers as homocysteine, urea, gamma-glutamyl transpeptidase, alkaline phosphatase, creatine phosphokinase, cholinesterase, and uric acid was shown. No significant differences were detected when we performed a comparative assessment of biochemical blood parameters following plasmapheresis with or without albumin replacement on biochemical blood parameters. Stable hemodynamic parameters during plasmapheresis and the absence of adverse reactions in patients confirm the safety and tolerability of the therapeutic plasmapheresis procedure. CONCLUSION. Implementing this technique into clinical practice will allow the development of approaches to etiotropic therapy of many chronic age-related pathologies. These treatments have the potential to increase life expectancy and improve its quality.